Market assessment of tuberculosis diagnostics in India in 2013

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 3, 2016, Pages 304-313

  Maheshwari, P ^a   Chauhan, K ^a   Kadam, R ^a   Pujani, A ^a   Kaur, M ^a   Chitalia, M ^a   Dabas, H ^a   Perkins, M D ^b   Boehme, C C ^b   Denkinger, C M ^b   Raizada, N ^b   Ginnard, J ^c   Jefferson, C ^d   Pantoja, A ^e   Rupert, S ^e   Kik, S V ^f   Cohen, C ^f   Chedore, P ^f   Satyanarayana, S ^f   Pai, M ^f  

^a CLINTON HEALTH ACCESS INITIATIVE   (United States)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^c Program Division Unitaid   (Switzerland)

^d FIND   (United States)

^e Department of Epidemiology and Biostatistics ^*  (Netherlands)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Costs; Diagnosis; Tests; Volumes

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; DIAGNOSTIC TEST; HEALTH CARE COST; HUMAN; INDIA; INTERFERON GAMMA RELEASE ASSAY; MARKET; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; SPECIES DIFFERENTIATION; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; TUBERCULIN TEST; TUBERCULOSIS; ECONOMICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; PRIVATE SECTOR; PUBLIC SECTOR; SENSITIVITY AND SPECIFICITY; SPUTUM;

HUMANS; INDIA; INTERFERON-GAMMA RELEASE TESTS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; PRIVATE SECTOR; PUBLIC SECTOR; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84958536139     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0571     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539.
3. Satyanarayana S, Nair S A, Chadha S S, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community-based survey of 30 districts. PLOS ONE 2011; 6: e24160.
4. Sreeramareddy C T, Qin Z Z, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. Int J Tuberc Lung Dis 2014; 18: 255-266.
5. Kik S V, Denkinger C M, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014; 44: 537-540.
6. Dheda K, Theron G,Welte A. Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. Lancet Global Health 2014; 2: e554-556.
7. Abu-Raddad L J, Sabatelli L, Achterberg J T, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 13 980-13 985.
8. Dheda K, Ruhwald M, Theron G, Peter J, Yam W C. Point-of-care diagnosis of tuberculosis: past, present and future. Respirology 2013; 18: 217-232.
9. Chandramouli C. Census of India 2011: rural urban distribution of population (provisional population totals). New Delhi, India: Ministry of Home Affairs, 2011. http://censusindia.gov.in/2011-prov-results/paper2/data-files/india/Rural-Urban-2011.pdf Accessed November 2015.
10. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis 2015; 211 (Suppl 2): S21-S28.
11. Pai M. Diagnostics for tuberculosis: what test developers want to know. Exp Rev Mol Diagn 2013; 13: 311-314.
12. World Health Organization/Special Programme for Research and Training in Tropical Diseases/Foundation for Innovative New Diagnostics. Diagnostics for tuberculosis. Global demand and market potential. Geneva, Switzerland: WHO, 2006.
13. Cobelens F, van den Hof S, Pai M, Squire S B, Ramsay A, Kimerling M E. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205 (Suppl 2): S191-S198.
14. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. PLOS ONE 2014; 9: e104105.
15. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in China in 2012. Int J Tuberc Lung Dis 2016; 20: 000-000.
16. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in South Africa, 2012-2013. Int J Tuberc Lung Dis 2015; 19: 216-222.
17. Central TB Division. TB India 2014. Revised National TB Control Programme. Annual status report. New Delhi, India: Ministry of Health and Family Welfare, Central TB Division, 2014.
18. Sahoo A. A short study on the patients' attitude towards the Indian diagnostics industry. Int J Adv Sci Tech Res 2013; 4: 396-403.
19. National Accreditation Board for Testing and Calibration Laboratories. Accredited laboratories. New Delhi, India: NABL, 2015. http://www.nabl-india.org/Accessed November 2015.
20. Central TB Division. Diagnosis of smear-positive pulmonary TB. New guidelines, effective from 1st April 2009. New Delhi, India: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, 2009: p 5.
21. Jaroslawski S, Pai M. Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Global Health 2012; 2: 39-50.
22. World Health Organization. Tuberculosis: serodiagnostic tests policy statement 2011. Geneva, Switzerland: WHO, 2011.
23. Steingart K R, Ramsay A, Dowdy DW, Pai M. Serological tests for the diagnosis of active tuberculosis: relevance for India. Ind J Med Res 2012; 135: 695-702.
24. Pai M. Promoting affordable and quality tuberculosis testing in India. J Lab Physicians 2013; 5: 1-4.
25. Social and Rural Research Unit, Indian Market Research Bureau. TB diagnostics in India's private sector: report on study findings. New Delhi, India: Clinton Health Access Initiative, 2015.
26. World Bank. Official exchange rate 2013. Washington DC, USA: World Bank, 2013. [cited 04/02/2015]. http://data. worldbank.org/indicator/PA.NUS.FCRF.
27. Rupert S, Vassal A, van't Hoog A. Costing analysis of the Xpert MTB/RIF in India. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2014.
28. Shekhar Menon M V M, Chitalia M, Pai M. TB diagnostics in India: market analysis and potential. Montreal, SC, Canada: McGill University, 2012. http://tbevidence.org/wp-content/uploads/2012/07/TB-Diagnostics-Market-Analysis-July16-2012-FINAL.pdf. Accessed November 2015.
29. Udwadia Z F, Pinto L M, Uplekar M W. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLOS ONE 2010; 5: e12023.
30. Wells WA, Ge C F, Patel N, Oh T, Gardiner E, Kimerling M E. Size and usage patterns of private TB drug markets in the high burden countries. PLOS ONE 2011; 6: e18964.
31. Global Tuberculosis Community Advisory Board, Treatment Action Group. Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries. New York, NY, USA: TAG, 2013. http://www.treatmentactiongroup.org/tb/advocacy/marketing-and-use-quantiferon-tb-gold. Accessed November 2015.
32. Aziz R. TB advocates urge action over misleading blood tests. Arlington, VA, USA: Center for Global Health Policy, 2013. http://sciencespeaksblog.org/2013/07/12/tb-advocates-urgeaction-over-misleading-blood-tests/Accessed November 2015.
33. Little K, Pai M, Dowdy D. Costs and consequences of using interferon-c release assays for the diagnosis of active tuberculosis in India. PLOS ONE 2015; 10: e0124525.